Pfizer (PFE) Tax Provisions (2009 - 2026)

Pfizer (PFE) has 18 years of Tax Provisions data on file, last reported at $461.0 million in Q1 2026.

• Tax Provisions for Q1 2026 came in at $461.0 million, up 343.92% year-over-year; the trailing twelve-month figure through Mar 2026 was $384.0 million (up 88.24% YoY), and the FY2025 annual result was -$266.0 million, down 850.0% from the prior year.
• Tax Provisions advanced to $461.0 million in Q1 2026 per PFE's latest filing, from -$2.0 million in the prior quarter.
• Over five years, Tax Provisions peaked at $1.6 billion in Q3 2022 and troughed at -$964.0 million in Q4 2023.
• A 5-year average of $172.4 million and a median of $141.0 million in 2025 frame the typical range for Tax Provisions.
• The sharpest annual moves came in 2023 and 2026: Tax Provisions slumped 370.79% in 2023, then jumped 343.92% in 2026.
• A 5-year view of Tax Provisions shows it stood at $356.0 million in 2022, then slumped by 319.1% to -$780.0 million in 2023, then soared by 130.0% to $234.0 million in 2024, then tumbled by 100.85% to -$2.0 million in 2025, then soared by 23150.0% to $461.0 million in 2026.
• Business Quant data shows PFE's Tax Provisions at $461.0 million in Q1 2026, -$2.0 million in Q4 2025, and -$216.0 million in Q3 2025.